Chk1 inhibition as a novel therapeutic strategy in melanoma

Melanoma patients respond poorly to chemotherapies because they acquire drug resistance. Therapies that can overcome the resistance to inhibitors of the mutated BRAF protein kinase in melanoma are urgently needed. Chk1 protein kinase is a central component of the DNA damage response and plays a cruc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Bor-Jang, Adhikary, Gautam, Eckert, Richard L., Lu, A-Lien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084399/
https://www.ncbi.nlm.nih.gov/pubmed/30100999
http://dx.doi.org/10.18632/oncotarget.25765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084399/
https://www.ncbi.nlm.nih.gov/pubmed/30100999
http://dx.doi.org/10.18632/oncotarget.25765

Ejemplares similares